Health

FDA Reconsiders Unapproved ‘Peptide’ Shots Marketed for Muscle, Fat Loss, Healing and Anti-Aging After Black-Market Boom

The Food and Drug Administration has opened the door to a possible regulatory shift on a group of peptide injections that have become wildly popular in wellness, fitness and anti-aging circles, but that remain unapproved as drugs. In a notice issued Tuesday, the FDA said its Pharmacy Compounding Advisory Committee will meet July 23 and 24 to examine whether seven peptides should be allowed onto the Section 503A bulks list, a step that could eventually permit more licensed compounding pharmacies to make them again for individual patients. The move does not approve the products as safe and effective drugs, and it does not immediately restore broad access. What the FDA announced is specific and technical, but the implications are broad. The agency said the July 23 session will review BPC-157, KPV, TB-500 and MOTs-C. On July 24, the panel will review emideltide, also known as delta sleeping inducing peptide or DSIP, along with semax and epitalon. The uses FDA says it evaluated for thes...